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Mechanical ventilationAbstract In clinical practice, physicians have recently attempted to avoid mechanical ventilation
(MV) as much as possible and have started to use non-invasive ventilation (NIV) in patients with
respiratory failure. A prospective observational study was conducted to assess the applicability,
effectiveness, and safety of NIV in managing patients with respiratory failure in Palestine. Fifty-
two patients (39 patients from West Bank and 13 patients from Gaza Strip) who fulﬁlled criteria
for inclusion were admitted to the two medical care units of the An-Najah National Teaching Hos-
pital during a 10-month period. These patients formed the study population to receive NIV. The
results came with baseline (mean ± SD) pH, PaO2, and PaCO2 measurements of 7.36 ± 0.1,
75.62 ± 32.7, and 46.5 ± 20.86 mmHg, respectively. The primary indication for NIV was hypox-
emic respiratory failure (n= 38, 73%). The success rate with NIV was 78%, with 40 out of 52
patients weaned successfully. Signiﬁcant improvements were observed in the ﬁrst hour following
institution of NIV in pH (7.38 ± 0.07, P< 0.001), PaO2 (90.4 ± 52.4, P< 0.001), and PaCO2
(40.4 ± 12.6, P< 0.001). These physiological parameters continued to improve up to the time of
weaning: pH (7.39 ± 0.07, P< 0.001), PaO2 (99.9 ± 44.3, P< 0.001), and PaCO2 (38.6 ± 13.9,
P< 0.001). The parameters were maintained within 12 h post-weaning: pH (7.39 ± 0.08,
P< 0.001), PaO2 (97 ± 30.3, P< 0.001), and PaCO2 (36.9 ± 10.3, P< 0.001). This study has
shown beneﬁts of NIV in avoiding the call for invasive MV in patients exhibiting respiratory failure
of varied etiology, with similar results comparable to previous studies in developed countries. Thus,
Table 1 Primary indication for NIV
than one diagnosis and cause for re
Diagnosis at admission
COPD
Pneumonia (community acquired pneu
Cardiogenic Pulmonary edema
Obesity/hypoventilation syndrome
Weaning from intubation
Neuromuscular disorders
Pleural eﬀusion
30 B.J. Ibrahim, D.K. Jaberincreased usage of NIV in respiratory failure is likely to affect favorably in countries with limited
resources such as Palestine.
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Respiratory failure is a common cause of illness and death, the
cost to society in terms of lost productivity and shortened lives
is enormous [1]. Mortality rates in Intensive Care Units (ICUs)
in Europe were around 40% [2,3], and epidemiological studies
suggest that respiratory failure will become more common as
the population ages, increasing by as much as 80% in the next
20 years [1].
For many years, patients who developed respiratory failure
had to be put on invasive MV, but it caused many severe com-
plications in those patients, so the recent critical care literature
has shown an outburst of articles on non-invasive respiratory
ventilation for patients with respiratory failure of varied etiol-
ogy, with numerous published randomized controlled trials
and meta-analysis on this topic [4–8]. Abundant data support-
ing NIV impact on respiratory failure have been published
from the western countries [9–20], but hardly any data from
the Middle East.
Also, Palestinian hospitals lack any experience with NIV,
but the An-Najah National University teaching hospital has
recently started to equip their critical care centers (Intensive
Care Unit and Cardiac Care Unit) with non-invasive ventilator
and well-trained teams with critical care specialists and has
started dealing with patients from all over the West Bank
and Gaza Strip including those who are referred by the minis-
try of health. This study evaluates the applicability, effective-
ness, and safety of NIV as a ﬁrst-line intervention for
respiratory failure in this hospital. Also, we expect from this
study to increase the awareness in Palestinian health society
and the region of the NIV role in respiratory failure.
2. Subjects and methods
After approval by the local ethics committee of research insti-
tutions at the An-Najah National University, Nablus, Pales-
tine (Chairperson Prof. Samar Musmar) on December 23,
2012, we enrolled patients with respiratory failure who were
admitted to the two critical care units of An-Najah hospital
from the West Bank and Gaza Strip during the period fromand diagnosis at admission; the
spiratory failure.
No Success (%) R
in
8 6 (75) 2
monia) 13 6 (46.2) 7
15 11 (73.3) 4
4 3 (75) 1
18 15 (83.3) 3
4 4 (100) 0
3 3 (100) 0January 2013 to November 2013. After obtaining written
informed consent, the study sample consists of 52 patients with
a mean age of 59.6 and male predominance of 57%.
The inclusion Criteria were (1) patient with respiratory failure
with either [21]: (1) hypoxemic respiratory failure (type 1) deﬁned
by a PaO2 of <60 mmHg or PaO2 to FiO2 ratio > 300 mmHg
with a normal or low PaCO2, or (2) Hypercapnic respiratory fail-
ure (type 2) deﬁned by a PaO2 of <60 mmHg or PaO2 to FiO2
ratio > 300 mmHg and a PaCO2 of >45 mmHg; (2) patient
who had been on mechanical ventilation for a certain reason
and need to be weaned from intubation. Furthermore, patients
were divided into 7 diagnostic groups based on the condition
that participate respiratory failure, see Table 1.
Criteria for excluding patients from the study include: (1)
Inability of the patient to protect the airway (coma or seizure dis-
orders) requiring an endotracheal tube or to manage secretions;
(2) Systolic blood pressure less than 90 mmHg or use of vaso-
pressors (shock); (3) Electrocardiogram instability with evidence
of ischemia or ventricular arrhythmias; (4) Life-threatening hyp-
oxemia (O2 saturation < 80%, or PaCO2 > 60 mmHg on a
nonrebreathing face mask); (5) Agitation, lack of cooperation,
facial trauma, burns, or facial surgery.
Criteria for failure and stop of NIV and exit from the study
include: Development of conditions necessitating ETI, which
include: (1) inability to increase or stabilize gas exchange, fail-
ure to improve agitation from hypoxemia for type 1 and/or
hypercapnia for type 2 for 60 min; (2) hemodynamic or ECG
instability: bradycardia (heart rate < 60 beats/min), hypoten-
sion (systolic blood pressure < 90 mmHg), and respiratory
arrest; failure to maintain SpO2 > 88%, signiﬁcant metabolic
and/or respiratory acidosis (pH < 7.20); (3) inability to toler-
ate the face mask because of discomfort; (4) failure to improve
mental status within 60 min for the patient who was lethargic.
2.1. Procedures
The method of NIV is shown in Fig. 1. In this study, we used
the two main modalities of NIV: continuous positive airway
pressure (CPAP) which was used for hypoxemic respiratory
failure and bi-level positive air pressure (BIPAP) which wastotal number adds up to more than 52 as some patients had more
equired
tubation (%)
Predicted
mortality (SD)
Actual
mortality (%)
Duration of
NIV /days (SD)
(25) 40.7 (15) 0 (0) 1.8 (0.4)
(53.8) 33.4 (21.6) 1 (7.7) 2.8 (1.6)
(26.7) 27 (10.7) 1 (6.7) 1.7 (0.8)
(25) 42.3 (19) 0 (0) 1.3 (0.6)
(16.7) 29 (18.7) 0 (0) 1.8 (0.7)
(0) 23.9 (23) 0 (0) 1.5 (0.6)
(0) 27 (16.5) 0 (0) 1.5 (0.7)
Figure 1 Methodology of noninvasive ventilation.
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were not improving sufﬁciently on CPAP alone. The ventilator
(Puritan Bennett Co or Galileo) was connected with conven-
tional ventilator tubing to a clear, full-face mask (Phillips;
and Puritan Bennett Co) with two adult sizes: medium and
large. First, to reduce the risk of aspiration, the head of the
bed was raised to an angle of 45 and was kept elevated during
NIV. Then, the full-face mask was softly placed over the
patient’s face and was kept in position by a nurse for a few
minutes until the patient was comfortable and completely syn-
chronized with the ventilator. The mask was then secured by
head straps, avoiding a tight ﬁt. Also, a tincture of benzoin
was frequently smeared over the mask’s cushion to favor seal-
ing with the skin interface, in order to reduce air leakage. To
reduce skin necrosis over the nasal bridge and at other contact
sites and to seal air leaks, a skin patch was applied. Regarding
nasogastric suction, it was only administrated if the patient
was expected to develop gastric distention.
After the mask had been placed, a CPAP of 5 cm H2O was
applied and pressure support ventilation (PSV) was increased
to achieve tidal volume of 5–7 ml/kg, a respiratory rate of less
than 25 breaths/min, and patients relief until borderline 20 cm
H2O. While with BIPAP, we started with 10 cm H2O inspira-
tory positive airway pressure (IPAP) and 5 cm H2O expiratory
positive airway pressure (EPAP) with initial adjustments to
obtain tidal volume of 5–7 ml/kg. After that, subsequent
adjustments were based on arterial blood gas values with
CPAP increased from 2 to 3 cm H2O until borderline 15 cm
H2O; because it reduced venous return and patients with bor-
derline low blood pressure can become hemodynamically
unstable. While with BIPAP, if there is persistent hypercapnia,
IPAP was increased by 2 cm H2O, and if there is persistent
hypoxemia IPAP and EPAP were increased by 2 cm H2O with
maximal IPAP limit of 20–25 cm H2O and EPAP limit of 10–
15 cm H2O.
Ventilation was delivered continuously, with every 4–6 h of
continuous NIV; patients had periods of ‘‘rest’’ (20–30 min)
off the mask while receiving supplemental oxygen, ﬂuids, or die-
tary liquid supplements with aminimal duration of 16 h per day.
During the weaning phase, with CPAP; patients were
weaned from NIV following improvement in respiratory fail-
ure by titrating periods off NIV to patient tolerance andobjective ﬁndings and then removing the ventilator once the
pressure is 5 cm H2O or less. Patients then received supplemen-
tal oxygen by nasal cannula or face mask. While with BIPAP;
IPAP was decreased to 7–9 cm H2O by decreasing 2–3 cm H2O
every time based on objective ﬁnding, then switching the set-
ting to intermittent use.
Patients received continuous ECG and arterial oxygen sat-
uration monitoring. Patients were examined at regular inter-
vals for abdominal distension and for their ability to clear
secretions or to protect the airways. Standard therapy directed
toward the etiology of the underlying condition and cause of
respiratory failure was maintained during NIV (e.g. patients
continued to receive bronchodilator therapy, etc).
The demographic features of patients were recorded, which
include age, sex, etiology, type of respiratory failure, perfor-
mance of the patient, and the presence or absence of associated
co-morbid illnesses. We collected the data for arterial blood
gases (pH, PaO2, FiO2, and PaCO2) at baseline, one hour, four
hours, and before discharge. The disease severity was calcu-
lated using the Acute Physiology and Chronic Health Evalua-
tion (APACHE II) scores. Pneumonia was deﬁned as the
presence of a new or progressive radiographic inﬁltrate plus
at least two of three clinical features (fever greater than 38C,
leukocytosis or leukopenia, and purulent secretions) [22].
Microbial conﬁrmation was limited because of the inability
to get specimens from the lower respiratory tract by bronchos-
copy as it is an invasive procedure. We also recorded patient
outcomes, regarding the time spent on NIV, length of ICU
stay, length of hospital stay, and patient discharge status.
Another complication of NIV is barotrauma, which is deﬁned
as the presence of air in the extra-alveolar spaces, such as
pneumothorax or pneumomediastinum, due to local overinﬂa-
tion caused by high distending pressure [23].
2.2. Data analysis
Statistical analysis was performed using SPSS version 20.
Parametric (t-test) or nonparametric (Mann–Whitney) analysis
was used, depending on whether variable distribution was nor-
mal or non-normal. Fischer’s exact test was applied to the cat-
egorical variables due to small expected frequencies, and
statistical signiﬁcance was assumed at a p-value less than
32 B.J. Ibrahim, D.K. Jaber0.05. Also, regarding ABG data (Ph, PaO2, PCO2), multiple
analysis of variance (MANOVA) was applied with perfor-
mance adjusted for multiple comparison.
3. Results
Over the 10-month period of the study, the number of patients
receiving mechanical ventilation with either ETI or NIV in the
two medical care units of the An-Najah National University
teaching hospital was 86, an average of 2 per week. During
that interval, NIV was attempted in 52 cases (60%) that ful-
ﬁlled the criteria for inclusion and initiation of NIV. It was
successful in avoiding intubation in 77% (40/52) of the patients
in whom it was attempted and in 47% (40/86) of all patients
receiving mechanical ventilation. Most patients in whom
NIV was not attempted had received ETI in the emergency
department or ward prior to contact by the critical care team
because they met the exclusion criteria of this study. The aver-
age number of patients attempted on NIV increased from eight
per month to 10 per month in the last month. Nine patients
received NIV in the cardiac care unit and 43 received it in
ICU. The study population was divided into two groups: hyp-
oxemic respiratory failure with a success rate of 78.9% (30/38)
and hypercapnic respiratory failure with a success rate of
71.4% (10/14), see Tables 2 and 3.
The study population had a mean (SD) APACHE II score
of 17.81 (7.01) with common indications being weaning from
intubation and cardiogenic pulmonary edema, see Table 1.
NIV with a mean (SD) period of 1.88 (0.983) days was
effective in improving physiological parameters throughout
the treatment in all except 12 patients, see Table 3 and Figs. 2–
4. In Table 4, although the APACHE scores of the patientsTable 3 Physiological parameters before, during and after NIV; all
SD expressed in parentheses.
Variable Before NIV 1 h after NIV
Type 1 Type 2 Type 1 Typ
PH 7.38 (.08) 7.29 (.11) 7.39 (.06) 7.35
PaCO2 (mm Hg) 36.9 (10.3) 72.6 (20) 34.3 (5) 56.6
PaO2/FiO2 209 (92) 286 (186) 239 (101) 234
Table 2 Baseline characteristics were available in all; all values exp
percentage and number in parentheses.
Type 2 (N= 14)Characteristic
Mean value (SD)
Age (years) 72.4 (14.7)
Gender (%Male) 57.1 n= 14
Apache II score 20 (5.2)
Predicted Mortality 36.7 (18.2)
Duration of NIV 1.79 (0.9)
Actual mortality 0
pH before NIV 7.38 (0.08)
PaO2/FiO2 before NIV 285.5 (186.5)
PaCO2 (mmHg) before NIV 72.6 (20.1)
Presence of other Co morbid illness 85.7
Success (number) 71.4 (10)who failed NIV were lower (16.9) than those who were success-
ful (18), this did not reach statistical signiﬁcance (p-
value = 0.62). The only signiﬁcant differences observed in
baseline characteristics of patients who failed NIV versus those
who succeeded are the mean age of the failed group was higher
(70) than that in the success group (56) (p-value = 0.036) and
the duration of ICU stay was higher (10) in the failed group
than in the success group (4) (p-value > 0.001). Of the 12
patients for whom NIV failed, two (4%) patients actually died
while mortality rate in the previous meta analysis study was
8% [6]. One of them had multiple comorbid illnesses with a
predicted mortality of 42% and died of heart failure and
hemodynamic instability; the other patient also had a comor-
bid illness with a predicted mortality of 21% but died of sud-
den hypotension due to cardiogenic shock and hemodynamic
instability that had no relation to NIV. Also, most of the
patients who failed on NIV had a hemodynamic instability
(7/12) that occurred during the study, which would meet the
exclusion criteria for not initiating the NIV. Reasons for dis-
continuation of NIV are shown in Table 5.
The most common problem faced with NIV was air leaks
from the masks; this was caused by ill-ﬁtting masks and with
the use of appropriately sized masks, it was minimized. Com-
plications of NIV were very rare in this study, occurring only
in 2 patients (3.8%), one with excessive secretion and the other
with gastric distension that required the insertion of a nasogas-
tric tube. Mask intolerance occurred in 2 patients (3.8%) this
result is very low compared to previous studies that report
about 30–50% of mask complication [24,25]. This fact could
be due to full time care given to patients by excellently taught
nurses.
Neither developed another complication of mechanical ven-
tilation, such as facial skin necrosis, nosocomial pneumonia,values are expressed as Mean and Standard deviation (SD) with
Prior to weaning Post weaning
e 2 Type 1 Type 2 Type 1 Type 2
(.06) 7.40 (.06) 7.35 (.07) 7.39 (.06) 7.35 (.09)
(12.5) 33.2 (5.7) 53.4 (18.5) 33 (6.5) 46.3 (12.7)
(104) 270 (100) 235 (100) 310 (135) 278 (110)
ressed as mean (standard deviation) except success expressed as
Type 1 (N= 38)
Range Mean value (SD) Range
39–91 54.9 (19.9) 19–98
55.3 n= 21
12–29 17 (7.5) 3–49
14.6–73 28.6 (17.3) 3.4–94
1.92 (1.02)
5.3
7.2–7.6 7.3 (0.1) 7.2–7.5
116.6–835.7 209.2 (92.4) 57–392.9
46–103 36.9 (10.3) 20–75
76.3
78.9 (30)
Figure 2 Changes in PH before NIV, at one hour, prior to weaning and after weaning (before discharge from the hospital), represented
by mean and standard deviation.
Figure 3 Changes in PaCO2 before NIV, at one hour, prior to weaning and after weaning (before discharge from the hospital),
represented by mean and standard deviation.
Figure 4 Changes in PaCO2 before NIV, at one hour, prior to weaning and after weaning (before discharge from the hospital),
represented by mean and standard deviation.
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not related to the use of higher pressure ventilation, and it
was not associated with clinical aspiration; it occurred becausethe patient had bowel ischemia that happened after initiation
of NIV. No serious complications occurred as a result of delay-
ing intubation in patients failing NIV.
Table 4 Correlates of outcomes of Non invasive ventilation.
Variable NIV success (N= 40) NIV failed (N= 12) P-Value Conﬁdence intervalc
Minimum Maximum
Agea 56.5 ± 20.2 70.3 ± 16.3 0.04 26.6 .95
PH before NIVa 7.35 ± 0.09 7.36 ± 0.11 0.8 .06 .07
Duration of care unit stay (days)b 4 (14) 10.5 (26) 0.001 11.04 .14
Duration of NIV (days)b 2 (4) 1 (3) 0.6 .5 .8
Hospital length of stay (days)b 8 (50) 14 (39) .08 12.4 .7
Number of patients survived 40 10 NA NA NA
Number of patients died 0 2 NA NA NA
APACHE IIa 18.1 ± 7.7 16.9 ± 4.3 0.6 3.5 5.8
PaCO2 before NIV
a 48.1 ± 21.5 41.1 ± 18.2 0.7 17.9 25.7
PaO2/FiO2 before NIV
a 235.6 ± 126.5 210.5 ± 134.2 0.6 59.7 109.7
Predicted Mortality 31.9 27.1 0.4 6.9 16.6
NA – not applicable.
a Mean + standard deviation.
b Median + range.
c 95% conﬁdence interval for difference between the two groups.
Table 5 Reasons for discontinuation of NIV and need for
intubation.
Parameters Numbers
Intolerance of mask 2 (3.8%)
Excessive secretions 1 (2%)
Nasal bridge erosions 0
Inability to correct ABG values 1 (2%)
Inability to decrease dyspnea 1 (2%)
Hemodynamic instability 7 (13%)
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The recent increase in the use of NIV in the critical care units
has been motivated by the desire to minimize complications of
invasive ventilation and to improve resource utilization. The
use of NIV in treating of respiratory failure with diverse etiol-
ogy is now supported by randomized controlled trials and
meta-analysis [4–8,26]. In these studies, NIV was associated
with a reduced need for invasive mechanical ventilation [4,6–
8,26], shortened length of hospital stay [6], and decreased mor-
tality [5–8]. Within the context of a prospective observational
study, this current study reports a success rate for NIV using
CPAP or BIPAP; NIV was successful in 78% of patients.
These results are consonant with previously published studies
reporting success rates 50–80% with NIV for acute respiratory
failure [4–8]. It is interesting to note that hypoxemic patients
formed a signiﬁcant (73%, N= 38) proportion of patients in
our study. Of these, 18 (34%) patients were on NIV to wean
from mechanical ventilation, with an 80% success rate, and
15 (29%) patients had cardiogenic pulmonary edema (CPE),
with a 76% success rate. NIV was beneﬁcial in patients pre-
senting with CPE in RCTs and meta-analysis studies [7]. While
23% (N= 14) of patients had hypercapnic respiratory failure,
with 8 (15%) patients having chronic obstructive pulmonary
disease (COPD), diagnosed according to their history, physical
examination ﬁndings, and pulmonary function tests. High suc-
cess has been described with NIV in a previous study of
patients exhibiting hypercapnic respiratory failure [4]. In asimilar study population of hypercapnic patients with a mean
baseline of PaCO2 of 70 mmHg, there was a 74% (32/43) suc-
cess rate when managed by NIV [4]. It is interesting that 4
(8%) patients in this current study had coexistent obesity that
may have contributed to respiratory failure. All of these
patients did ﬁne on NIV. Former studies have reported
improvements in clinical and biochemical parameters in
patients with obesity hypoventilation syndrome [27,28].
In this study, the clinical improvement of patients on NIV
was conﬁrmed by improvements in the physiological variables.
There was a signiﬁcant improvement (P-value > 0.05) in the
average PH, PaCO2, and PaO2 levels within hours of applica-
tion of NIV, see Figs. 2–4. These improvements are similar to
those published in a literature in a similar population of
patients [4–8]. The severity of illness at presentation, as dis-
played by the APACHE ll score, is postulated to inﬂuence
response to NIV. Although two studies [29,30], demonstrated
propensity for failure with NIV in patients with higher
APACHE ll scores, this observation has not been supported
by other studies [31,32]. The mean (SD) APACHE ll score in
the current study was 17.81 (7.01). Although the mean
APACHE ll scores were higher between responders (18.075)
compared to non responders (16.916), this difference was not
statistically signiﬁcant (P= 0.62). The tendency toward a
longer duration of hospitalization in patients for whom NIV
failed in the current study, compared to those who were trea-
ted successfully, may be due to early deaths in those who failed
NIV. This was not statistically signiﬁcant (P= 0.077), but
ICU stay was (P= 0.001); patients for whom NIV failed
had a longer duration of ICU stay than those for whom
NIV was successful.
The duration of NIV in hypoxemic respiratory failure
patients with mean (SD) period was 1.92 (1.02) days which rep-
resents the same result as previous studies [23,33]. While the
duration in hypercapnic with mean (SD) period was 1.79
(0.9), which is longer than the previous study of mean 26 h
[34]. Regarding etiology of NIV the longer duration for com-
munity acquired pneumonia with mean (SD) period was 2.88
(1.6), which is the same as other study [35]. And shorter dura-
tion for obesity/hypoventilation syndrome with mean (SD)
period was 1.3 (0.6), see Table 2.
Effectiveness of non-invasive ventilation in management of respiratory failure 35NIV aims to eliminate the complications of invasive MV,
such as ventilator-associated pneumonia (VAP) and baro-
trauma. VAP rates are high in patients put on MV, with 8–
28% of patients developing this problem [36], and about
21.6% here in Palestine in 2013 [37]. No patients in our study
revealed a new inﬁltration on the X-ray associated with fever,
tachypnea, or leucocytosis that could suggest nosocomial
pneumonia.
The ﬁndings of this prospective observational study con-
ﬁrm other previous reports on the effectiveness of NIV in man-
aging patients with respiratory failure. However, this study did
not evaluate determinants of success of NIV (such as level of
consciousness, BMI, hemodynamic state, respiratory rate,
etc.), which could be considered a limitation. However, it is
worthwhile to mention that the functional status before respi-
ratory failure was much better in the NIV responder group
compared with NIV nonresponders. The same thing was
observed with regard to comorbidities, which were higher in
NIV nonresponders than in NIV responders; this could be
used to predict the failure or success of NIV. Despite these lim-
itations, this study has demonstrated that NIV is not only a
feasible ventilatory modality in Palestine, but is also a treat-
ment that is correlated with signiﬁcant improvements in phys-
iological and clinical outcomes. The application of NIV
resulted in low rates of endotracheal intubation and fewer
complications, and was well tolerated in our study population,
although a cost-beneﬁt analysis would have granted a credit to
NIV use in Middle Eastern countries, especially ours. The
lower cost of non-invasive ventilators (compared to standard
invasive ventilators), reduced length of stay in the hospital,
and lower complication rates are likely to translate to desirable
economic beneﬁts, although further studies with larger sample
sizes are needed to prove that.
Further implications regarding the use of NIV need to be
addressed in the context of the Ministry of Health of Palestine.
Newer modalities of treatment, such as NIV, demand trained
teams that can not only implement such therapies, but also
allow such treatments to translate to improvements in patient
and clinical outcomes. I was fortunate to have a critical care
specialist who obtained skills in NIV abroad and who conse-
quently trained the devoted medical and nursing teams and
the respiratory therapists on the use of NIV and supervised
patient care. Within a few months, NIV became an indispens-
able part of the respiratory support of the A-Najah National
University teaching hospital’s two care units. NIV has become
the preferred initial treatment of patients with hypercapnic
respiratory failure and in those with hypoxemic respiratory
failure in whom the clinical condition can be readily reversed
(48–72 h), when airway control is not needed, and the patient
is hemodynamically and electrocardiographically stable.
Also, it is worth to mention that this can be achieved with-
out any increase in the nursing and technical staff that looks
after such patients. Also, there was no additional cost of buy-
ing dedicated non-invasive ventilators, because the modern
ventilators can be used for both invasive and non-invasive ven-
tilation. It would be interesting to evaluate, in future studies,
factors that can predict the success or failure of NIV, or study
the effectiveness of NIV in a particular type of respiratory fail-
ure (like type 1, type 2, COPD, CPE, obesity, etc.) as this mode
of treatment could gain wide acceptance as a primary tech-
nique of treatment in the region for patients exhibiting respira-
tory failure.Conﬂict of interest
We have no conﬂict of interest to declare.Supplementary data associated with this article can be found,Appendix A. Supplementary data
in the online version, at http://dx.doi.org/10.1016/j.ejccm.20
14.07.002.
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